Orexo initiates exploratory feasibility studies of amorphOX[®] with two leading biopharmaceutical and vaccine companies
· Orexo has successfully formulated Covid-19 spike protein in the proprietary drug delivery platform amorphOX®, showing excellent protein stability · Orexo has initiated two exploratory feasibility studies applying amorphOX[®] to a protein based pharmaceutical and a vaccine in collaboration with leading international biopharmaceutical and vaccine companies · Orexo has patent applications for amorphOX[®] formulations relating to biomolecules Uppsala, Sweden – January 9, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory